ClinicalTrials.gg
Active, not recruitingNCT06421935Updated Sep 9, 2026

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

A Phase 1 interventional study of M9466 and Tuvusertib in Advanced Solid Tumor, sponsored by EMD Serono Research & Development Institute, Inc.. Active, not recruiting at 20 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Ovarian Neoplasms by Merck KGaA, Darmstadt, Germany — 1 open to participants now, 3 under way, 1 of them phase 3. Ovarian Neoplasms · Merck KGaA, Darmstadt, Germany.

Enrollment
6th of 12
60 · median 57
Started
2024
with 1 other
Phase 1
6 of 12
1 open now
Registered
10th of 12
by date

Among the 12 studies in Ovarian Neoplasms by Merck KGaA, Darmstadt, Germany, this one is the 6th largest by enrollment, is one of 2 that started in 2024, is one of 6 in phase 1, and was the 10th registered.

Ovarian Neoplasms

3,389 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

1 of the 12 studies in Ovarian Neoplasms by Merck KGaA, Darmstadt, Germany is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Ovarian Neoplasms by Merck KGaA, Darmstadt, Germany, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic profile of M9466 with and without tuvusertib or an ARPi and early signs of clinical activity of M9466 with tuvusertib in participants with advanced solid tumors. Study details include: Study/Treatment Duration: Participants will be treated until disease progression, death, discontinuation, or End of Study. Visit Frequency: Every week in the first 2 cycles, followed by every 3 weeks in the subsequent cycles. An End of Treatment Visit and Safety Follow-up/Discontinuation Visit are scheduled after the treatment period.

03

Conditions studied

  • Advanced Solid Tumor

Browse trials for

Keywords

  • PARP inhibitor
  • castration-resistant Prostate cancer
  • ovarian cancer
  • Abiraterone Acetate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Module 1 Part A and Module 2 Part A1: Locally advanced or disease that is to standard therapy or for which no standard therapy is judged appropriate by the Investigator
  • Module 1 Part A2: or pathologically confirmed advanced or metastatic CRPC or EOC
  • Performance Status less than or equal to (\<=) 1
  • of more than 6 months
  • Have adequate hematologic function
  • Participants who received chemotherapy, extensive radiotherapy, biological therapy (e.g. antibodies) or agents will have a of 4 weeks (6 weeks for nitrosourea, mitomycin-C) or 5 half-lives whichever is shorter, prior to starting study intervention with M9466 (± tuvusertib)
  • Module 3 Part A1:

    • Histologically or pathologically confirmed diagnosis of prostate cancer
    • Metastatic disease documented by positive bone scan or metastatic lesions on CT or MRI
    • Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC) are allowed. For mCRPC, serum testosterone levels ≤ 50 /dL (≤ 1.75 nmol/L).
    • Ongoing ADT with a GnRH agonist or antagonist for participants who have not undergone bilateral orchiectomy must be initiated before first dose and must continue throughout the study.
    • Candidate for treatment with ·abiraterone acetate.
    • Prior anticancer therapy allowed for mHSPC or mCRPC
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Persistence of Adverse Events related to any prior treatments that have not recovered to Grade less than 1 by NCI - v5.0 unless AEs are clinically nonsignificant and/or stable on supportive therapy in the opinion of the Investigator (e.g. neuropathy or alopecia)
  • Participant has a history of additional within 5 years before the date of enrollment other than disease under study (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, benign prostate neoplasm/hypertropia, or malignancy that in the opinion of the Investigator, with concurrence of the Sponsor's Medical Monitor, is considered cured with minimal risk of recurrence within 3 years)
  • Participants with known , except if clinically controlled, which is defined as individuals with Central Nervous System (CNS) tumors that have been treated, are asymptomatic and who have discontinued (for the treatment of CNS tumors) for more than 28 days
  • Serious Gastrointestinal bleeding within 3 months, nausea and vomiting, uncontrolled diarrhea, known malabsorption, significant small bowel resection or gastric bypass surgery, use of feeding tubes, other chronic gastrointestinal disease (including exocrine pancreatic insufficiency requiring pancreatic enzyme replacement therapy), and/or other situations that may preclude adequate absorption of oral medications
  • Cerebrovascular accident or stroke
  • Module 3 only:

    • Current evidence of any of the following:

      1. Any medical condition that would make prednisone (or equivalent) use .
      2. Any chronic medical condition requiring a higher dose of corticosteroid than 10 mg prednisone (or equivalent) once daily.
    • History of uncontrolled pituitary or adrenal dysfunction
    • Hypokalemia
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    M9466 plus Tuvusertib

    Drug: M9466 · Drug: Tuvusertib

  • Experimental
    M9466 Monotherapy

    Drug: M9466

  • Experimental
    M9466 with AA-P(abiraterone acetate and prednisone or prednisolone)

    Drug: M9466 · Drug: Abiraterone acetate · Drug: Prednisone/Prednisolone

Interventions

  • DrugM9466

    Participants will be administered M9466 orally.

    Also known as: HRS-1167;

  • Participants will be administered Tuvusertib orally.

    Also known as: Substance code MSC2584415A; also known as M1774, VXc-400, or VR 1363004

  • Participants will be administered with Abiraterone acetate orally.

    Also known as: Abiraterone

  • DrugPrednisone/Prednisolone

    Drug pages: Prednisone · Prednisolone

    Participants will be administered with prednisone/prednisolone orally.

06

What researchers measure

Primary outcomes

  1. Module 1 Part A1 and Part A2: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Treatment-related AEs (TRAEs)

    Time frame: Time from first treatment up to 30 days after end of study intervention (approximately assessed up to 20 months)

  2. Module 1 Part A1 and Part A2: Number of Participants with Dose Limiting Toxicity (DLT)-like events

    Time frame: Day 1 up to Day 21 of Cycle 1 (each cycle is of 21 days)

  3. Module 2 Part A1: Pharmacokinetic (PK) Plasma Concentrations of M9466

    Time frame: Cycle 1 Day 1 (C1D1), C1D8 and C1D15

  4. Module 2 Part A2: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Treatment-related AEs (TRAEs)

    Time frame: Time from first treatment up to 30 days after end of study intervention (approximately assessed up to 20 months)

  5. Module 3 Part A1: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Treatment-related AEs

    Time frame: Time from first treatment up to 30 days after end of study intervention

  6. Module 3 Part A1: Number of Participants with Dose Limiting Toxicity (DLT)-like Events

    Time frame: Day 1 up to Day 21 of Cycle 1(each cycle is of 21 days)

Secondary outcomes

  1. Module 1 Part A1 and Part A2, Module 2 Part A1 and A2 and Module 3 Part A1: Pharmacokinetic (PK) Plasma Concentrations of M9466 and Tuvusertib

    Time frame: Module 1 Part A1: C1D1 and C1D5 or C1D6; Module 1 Part A2: C1D1, C1D2, C1D3 or C1D4 and C1D8; Module 2 Part A1: C1D1, C1D8 and C1D15; Module 2 Part A2: C1D1, C1D2 and C1D8, C1D22 and C2D1; Module 2 Part A1: C1D1 and C1D8

  2. Module 1 Part A1 and Part A2, Module 2 Part A2: Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (or PCWG3 for prostate cancer) as Assessed by Investigator

    Time frame: Time from first treatment to planned assessment at 12 months

  3. Module 1 Part A1 and Part A2; Module 2 Part A1 : Effect of M9466 in combination with tuvusertib on QTc interval as determined by Digital ECGs

    Time frame: Time from first treatment to planned assessment at 12 months

  4. Module 2 Part A1: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Treatment-Related AEs

    Time frame: Time from first treatment up to 30 days after end of study intervention (approximately assessed up to 20 months)

  5. Module 2 Part A1 and Part A2: Relative Changes in Pharmacodynamics Markers in Paired Tumor Biopsies

    Time frame: Day 1, Day 8 and Day 15

07

Study locations

20 sites
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared for Phase I interventional or observational studies. Further information on how to request data can be found on our website bit.ly/IPD21.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Feb 2027, 30 months after the start.

Of 210 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 30 months is below that.

Counting every sponsor, half of 380 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2024
First posted
May 20, 2024
StartActual
Aug 7, 2024
Primary completionEst.
Feb 22, 2027
CompletionEst.
Feb 22, 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06421935
Responsible party
Sponsor
First posted
May 20, 2024
Start date
Aug 7, 2024
Primary completion
Feb 22, 2027 (estimated)
Completion
Feb 22, 2027 (estimated)
Last update
Sep 9, 2026

Study contacts

Medical Responsible
study director · EMD Serono Research & Development Institute, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PARP1 Inhibitor HRS-1167

Start the discussion